From: Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
Patients dataa | Cmax on D1 | p | |
---|---|---|---|
< 64 mg/L | ≥ 64 mg/L | ||
(n = 56) | (n = 37) | ||
Female | 20 (35.7) | 17 (45.9) | 0.32 |
Age (years) | 60 [24–90] | 66 [46–88] | 0.038 |
BMI admission | 24.5 [15–42.4] | 25.4 [18.8–45.1] | 0.17 |
SAPS 2 admission | 51.5 [15–105] | 54 [29–124] | 0.38 |
Chronic renal failure | 7 (12.5) | 10 (27) | 0.10 |
Data on D1 | (n = 60) | (n = 38) | |
---|---|---|---|
Admission time—D1 (d) | 5 [1–71] | 4 [1–35] | 0.25 |
Weight (kg) | 75.5 [45–130] | 79.5 [48–120] | 0.15 |
Weight gain/admission (kg) | 0 [− 15–25] | 0 [− 12–23] | 0.26 |
SOFA | 6.5 [0–17] | 8 [0–15] | 0.17 |
Mechanical ventilation | 41 (68.3) | 21 (55.2) | 0.19 |
Vasopressor support | 32 (53.3) | 26 (68.4) | 0.14 |
Renal replacement therapy | 2 (3.3) | 3 (7.9) | 0.37 |
Urine 24 h volume (mL) | 1100 [0–5300] | 1225 [0–4900] | 0.52 |
Serum creatinine (µmol/L) | 58.5 [23–453] | 132 [31–609] | 0.0003 |
24-h fluid intake (mL) | 3200 [1000–12,642] | 2868 [1000–11,000] | 0.90 |
Dose administered per kg (mg) | 25 [15.6–31.8] | 25 [20.3–31.3] | 0.11 |
Total dose administered (mg) | 1800 [1000–3250] | 2000 [1250–3000] | 0.034 |